The notice adds that Fabiflu was not tested as monotherapy in any of the mild or moderate cases and that claims by the company were misleading.
Firm’s claim on Fabiflu’s effectiveness in patients under lens
The Drug Controller General of India (DCGI) has, earlier this week, issued notice to Glenmark Pharmaceuticals asking it to respond to allegations of overpricing and claim that its antiviral drug Fabiflu is effective in COVID-19 patients with co-morbidities.
The DCGI has sought a response from the company.
“It has been mentioned in representation that Glenmark has claimed that this drug is effective in co-morbid conditions like hypertension, diabetes whereas in reality, as per protocol summary, this trial was not designed to assess the Fabiflu in co-morbid conditions. No cl